HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Rose Sheet

Executive Summary

Energizer Holdings initiates a voluntary recall suggesting that users of its Banana Boat UltraMist continuous spray sunscreen products are still susceptible to burns, though not from the sun. More news in brief.

You may also be interested in...



Banana Boat Sunscreen Recall Could Raise Questions On Spray Standards

Energizer Personal Care’s recall of 23 Banana Boat spray sunscreen SKUs came in response to five reports of consumers burned after using the products. A broader problem may be the lack of a formal or recognized industry standard for dispensing volumes of continuous spray sunscreens.

Spray Sunscreen Safety Review Heats Up As FDA Looks Into Burn Report

FDA has launched an inquiry following a report that a consumer suffered second-degree burns after using a Banana Boat spray sunscreen from Energizer Personal Care. The firm submitted data to FDA demonstrating the safety and efficacy of spray sunscreens in support of their inclusion in the final monograph.

How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies

UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS018331

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel